tiprankstipranks
Advertisement
Advertisement
Stoke Therapeutics: Buy Rating Reiterated as Phase 3 Dravet Program Advances; $60 Price Target Maintained
PremiumRatingsStoke Therapeutics: Buy Rating Reiterated as Phase 3 Dravet Program Advances; $60 Price Target Maintained
2M ago
Analyst Reiterates Buy on Stoke Therapeutics, Maintains $40 Price Target on Robust Dravet Data and Phase 3 Progress
Premium
Ratings
Analyst Reiterates Buy on Stoke Therapeutics, Maintains $40 Price Target on Robust Dravet Data and Phase 3 Progress
2M ago
Werber Reiterates Buy on Strong EMPEROR Phase 3 Progress, Durable Zorevunersen Data and Solid Cash Runway Through 2028
Premium
Ratings
Werber Reiterates Buy on Strong EMPEROR Phase 3 Progress, Durable Zorevunersen Data and Solid Cash Runway Through 2028
2M ago
Stoke Therapeutics price target raised to $60 from $36 at Canaccord
PremiumThe FlyStoke Therapeutics price target raised to $60 from $36 at Canaccord
4M ago
Stoke Therapeutics files automatic mixed securities shelf
Premium
The Fly
Stoke Therapeutics files automatic mixed securities shelf
4M ago
Stoke Therapeutics price target raised to $38 from $36 at Wedbush
Premium
The Fly
Stoke Therapeutics price target raised to $38 from $36 at Wedbush
4M ago
Stoke Therapeutics Awards Discretionary Bonus to CEO Smith
PremiumCompany AnnouncementsStoke Therapeutics Awards Discretionary Bonus to CEO Smith
5M ago
Stoke Therapeutics initiated with an Outperform at Wolfe Research
Premium
The Fly
Stoke Therapeutics initiated with an Outperform at Wolfe Research
5M ago
Stoke Therapeutics participates in a conf call hosted by Cantor Fitzgerald
Premium
The Fly
Stoke Therapeutics participates in a conf call hosted by Cantor Fitzgerald
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100